Previous close | 16.85 |
Open | N/A |
Bid | 20.00 |
Ask | 21.65 |
Strike | 61.00 |
Expiry date | 2024-05-31 |
Day's range | 16.85 - 16.85 |
Contract range | N/A |
Volume | |
Open interest | N/A |
PRINCETON, N.J., June 01, 2024--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.